AUSTIN, TX—Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), has reported selling shares of the company’s common stock totaling approximately $909,125. The transactions, executed on January 2, 2025, were conducted under a Rule 10b5-1 trading plan. The sale comes as Natera’s stock trades near its 52-week high of $175.63, having delivered an impressive 180% return over the past year. According to InvestingPro analysis, the company maintains a GOOD financial health rating despite current market valuation concerns.
The sales involved multiple transactions with prices ranging from $158.71 to $160.70 per share. Following these transactions, Jonathan retains direct ownership of 254,372 shares and indirect ownership of 44,782 shares through the Caraluna 1 and Caraluna 2 Trusts.
These sales are part of a pre-established trading plan, allowing insiders to sell a predetermined number of shares at set times.
In other recent news, Natera Inc (NASDAQ:). has expanded its patent infringement litigation against NeoGenomics (NASDAQ:), Inc., with the inclusion of an additional patent in the ongoing lawsuit. The company has also reported a record Q3 revenue of $439.8 million, marking a 64% increase year-over-year, and conducted 137,000 oncology tests, a 54% increase from the previous year. Analyst firms TD Cowen, Baird, and Jefferies have maintained favorable ratings on Natera’s stock and raised their price targets, reflecting confidence in the company’s future performance.
In other developments, Natera has amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role with conditions outlined in the agreement. However, the company faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), but plans to request the court to overturn the ruling. These recent developments provide investors with insights into Natera’s current status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
